1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

How The Prostate Cancer Market Will Look Over Next Decade

 
• By Kevin Grogan

As generic competition to J&J's Zytiga starts to line up ahead of possible launches in October, Datamonitor Healthcare has been weighing up the prostate cancer therapy space and seeing where the future competition will come from for Pfizer and Astellas' market leader Xtandi.

Consultation
The prostate cancer therapy market is set to keep growing • Source: Shutterstock

Now that Johnson & Johnson's blockbuster Zytiga (abiraterone acetate) is to be hit by generic competition later this year in the US, analysts at Datamonitor Healthcare have been looking at the next drivers of the prostate cancer market.

Earlier this month, the US Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) invalidated the composition and method...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 
• By Alaric DeArment

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

More from Therapy Areas

Replimune CRL Could Hold Warning For Accelerated Approvals

 
• By Jessica Merrill

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.